Ad hoc releases are announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
View Featured news and Pulse updates.
Header
Newsroom
Showing 1850 results
September 2023
-
Press release
Les actionnaires de Novartis approuvent le projet de scission à 100% de Sandoz
Les actionnaires approuvent le projet de scission à 100% de Sandoz, l’activité Génériques et Biosimilaires de NovartisLes actionnaires approuvent également une réduction du capital social dans le… -
Press release
Aktionärinnen und Aktionäre von Novartis stimmen dem geplanten 100% igen Spin-off von Sandoz zu
Die Aktionärinnen und Aktionäre stimmen dem geplanten 100%igen Spin-off von Sandoz, dem Generika- und Biosimilars-Geschäft von Novartis, zu.Die Aktionärinnen und Aktionäre stimmen ausserdem einer… -
Press release
Novartis Kisqali® reduced the risk of cancer recurrence while maintaining quality of life in patients diagnosed with early breast cancer
Patient-reported outcomes (PROs) from the Phase III NATALEE trial show that patients receiving adjuvant Kisqali plus endocrine therapy (ET) for up to three years maintained physical and social… -
Statement
Novartis provides support for Moroccan earthquake victims
-
Featured News
Novartis’ Giving & Volunteering wins ACCP’s 2023 Corporate Social Impact Team of the Year Award
-
Statement
GT005 (PPY988): Development Program in Geographic Atrophy
-
Press release
Sandoz announces exclusive deal to commercialize biosimilar ustekinumab, further reinforcing growing pipeline and immunology patient offering
Agreement with Samsung Bioepis gives Sandoz exclusive commercialization rights to biosimilar SB17 ustekinumab in Europe and North AmericaUstekinumab is a fully human monoclonal antibody to… -
Story Discovery
Treatments for blood cancers and serious blood disorders are advancing rapidly – Novartis is helping lead the way
Novartis has been at the forefront of advances in how blood cancers and serious blood disorders are treated, helping patients live their best lives.
-
Press release
Novartis appoints Patrick Horber, M.D., President, International as Marie-France Tschudin, President, Innovative Medicines International and Chief Commercial Officer, steps down from the Executive Committee of Novartis
After nearly seven years at Novartis and more than four years as a member of the ECN, Ms. Tschudin will pursue her next chapter of leadership outside of Novartis Dr. Horber to drive next phase… -
Press release
Novartis ernennt Dr. Patrick Horber zum President, International, da Marie-France Tschudin, President, Innovative Medicines International und Chief Commercial Officer, aus der Geschäftsleitung von Novartis ausscheidet
Nach fast sieben Jahren bei Novartis und mehr als vier Jahren als Mitglied der Geschäftsleitung wird Marie-France Tschudin ihr nächstes Führungskapitel ausserhalb von Novartis beginnen Dr. Horber… -
Press release
Novartis nomme Patrick Horber, Docteur en médecine, au poste de President, International, alors que Marie-France Tschudin, President, Innovative Medicines International et Chief Commercial Officer, quitte le Comité exécutif de Novartis
Après près de sept années chez Novartis et plus de quatre années en tant que membre du Comité exécutif de Novartis, Mme Tschudin poursuivra sa carrière de leader en dehors de Novartis Le Dr Horber… -
Ad hoc release
Sandoz publishes supplement to Listing Prospectus including Sandoz H1 2023 financial statements
Ad hoc announcement pursuant to Art. 53 LRSupplement published by Sandoz ahead of Novartis Extraordinary General Meeting on September 15, 2023H1 results demonstrated continued momentum with strong…